Ladenburg Thalmann Financial Services’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

Ladenburg Thalmann Financial Services’s Portfolio KDNY Stock Details KDNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-10	Closed	–	–	5371
2018 Q2	$0	Hold	10	–	–	﹤0.01%	5174
2018 Q1	$0	Buy	+10	New	+$366	﹤0.01%	5239
2016 Q1	–	Sell	-200	Closed	-$28K	–	4839
2015 Q4	$28K	Buy	+200	New	+$27.2K	﹤0.01%	2989

Other funds holding KDNY

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

ACM

Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

HMC

Harvard Management Company Boston, Massachusetts $1.82B AUM 26.23% 1-Year Est. Return

Ladenburg Thalmann Financial Services's KDNY Position: Q3 2018 in Review

Ladenburg Thalmann Financial Services sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q3 2018, closing a stake of 10 shares.

Ladenburg Thalmann Financial Services first reported a position in KDNY in Q4 2015 and held it in 3 quarters. The position peaked at $28K in Q4 2015. 87 funds tracked by Wall St. Rank hold KDNY as of Q3 2018.

Ladenburg Thalmann Financial Services reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q3 2018 after selling out during the quarter.
Ladenburg Thalmann Financial Services sold 10 Chinook Therapeutics, Inc. Common Stock shares in Q3 2018.
Ladenburg Thalmann Financial Services first reported a position in Chinook Therapeutics, Inc. Common Stock in Q4 2015 and held it in 3 quarters.
Ladenburg Thalmann Financial Services's Chinook Therapeutics, Inc. Common Stock position peaked at $28K in Q4 2015.
87 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q3 2018.

Based on Ladenburg Thalmann Financial Services's 13F filing for Q3 2018, filed 14 Nov 2018.